Longitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients (LET-PKD Study)
Unknown Not Applicable NCT02729662
Study Description
Investigation of the therapeutic effects of tolvaptan in patients with autosomal dominant polycystic kidney disease This is a prospective 5-year study to compare the change in total kidney volume (TKV) before and after tolvaptan therapy, as the primary endpoint, in patients with ADPKD. Study results will be summarized, analyzed, and compiled into a research paper at 5 years (data cut-off, Aug 31, 2020).
Study Details
- Registry ID:
- NCT02729662
- Conditions:
- Autosomal Dominant Polycystic Kidney Disease
- Phase:
- Not Applicable
- Target Enrollment:
- 118 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Kyorin University Hospital
Mitaka, Tokyo, Japan
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.